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Abstract
Background By the traditional definition of unintended weight loss, cachexia develops in ~80% of patients with pancreatic
ductal adenocarcinoma (PDAC). Here, we measure the longitudinal body composition changes in patients with advanced PDAC
undergoing 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin therapy.
Methods We performed a retrospective review of 53 patients with advanced PDAC on 5-fluorouracil, leucovorin, irinotecan,
and oxaliplatin as first line therapy at Indiana University Hospital from July 2010 to August 2015. Demographic, clinical, and
survival data were collected. Body composition measurement by computed tomography (CT), trend, univariate, and multivar-
iate analysis were performed.
Results Among all patients, three cachexia phenotypes were identified. The majority of patients, 64%, had Muscle and Fat
Wasting (MFW), while 17% had Fat-Only Wasting (FW) and 19% had No Wasting (NW). NW had significantly improved overall
median survival (OMS) of 22.6 months vs. 13.0 months for FW and 12.2 months for MFW (P = 0.02). FW (HR = 5.2; 95% confi-
dence interval = 1.5–17.3) andMFW (HR = 1.8; 95% confidence interval = 1.1–2.9) were associated with an increased risk of mor-
tality compared with NW. OMS and risk of mortality did not differ between FW and MFW. Progression of disease, sarcopenic
obesity at diagnosis, and primary tail tumours were also associated with decreased OMS. Onmultivariate analysis, cachexia phe-
notype and chemotherapy response were independently associated with survival. Notably, CT-based body composition analysis
detected tissue loss of >5% in 81% of patients, while the traditional definition of >5% body weight loss identified 56.6%.
Conclusions Distinct cachexia phenotypes were observed in this homogeneous population of patients with equivalent stage,
diagnosis, and first-line treatment. This suggests cellular, molecular, or genetic heterogeneity of host or tumour. Survival
among patients with FW was as poor as for MFW, indicating adipose tissue plays a crucial role in cachexia and PDAC mortality.
Adipose tissue should be studied for its mechanistic contributions to cachexia.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer deaths
in the United States and is on the rise.1 The ductal
adenocarcinoma (PDAC) subtype accounts for the majority
of cases of pancreatic cancer.1 Patients with PDAC typically
present late with advanced, unresectable disease and have
a dismal prognosis.2,3 Gemcitabine-based chemotherapy
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regimens have traditionally been the standard treatment pro-
tocol for unresectable PDAC. Unfortunately, most patients
will not respond and overall median survival (OMS) is only
6–9 months.2,3 The chemotherapy combination of
5-fluorouracil, leucovorin, irinotecan, and oxaliplatin
(FOLFIRINOX) has improved survival but the overall prognosis
remains exceedingly grim. Recent studies have shown
FOLFIRINOX to be superior to gemcitabine, however, OMS
still only approaches 15 months.4–8 Furthermore, FOLFIRINOX
is often poorly tolerated and dosing may need to be reduced
or completely discontinued due to severe side effects.5–9
Many patients with PDAC present with involuntary weight
loss. The vast majority of patients with PDAC will experience
severe wasting during the course of their illness, and cachexia
has been implicated as a significant cause of PDAC-related
deaths.10 Cachexia is associated with decreased tolerance of
and response to treatment, decreased quality of life,
decreased survival, and generally worse overall outcomes in
patients with malignancies, including PDAC.11–14 Thus,
although improving antitumour therapies is clearly indicated,
anti-cachexia therapy represents a major unmet need that
could promote survival in patients with PDAC.
Cachexia is defined as a complex metabolic derangement
characterized by loss of muscle with or without the loss of
fat that cannot be reversed by nutritional support.11 Cachexia
is not due solely to inadequate food intake, although there
are components of anorexia and malabsorption. Rather,
cachexia represents a shift in whole body fuel utilization
resulting in increased adipose lipolysis and reduced lipogene-
sis, and increased proteolysis but reduced structural protein
synthesis in skeletal muscle (SKM). As well, cachexia influ-
ences central mechanisms regulating appetite, activity, and
resting energy expenditure, and shifts hepatic gene expres-
sion and metabolism. Tissue inflammation and elevated
inflammatory cytokines in the circulation are hallmarks of
some forms of cachexia.
The consensus definition of cachexia in patients with
cancer is weight loss greater than 5%, or weight loss greater
than 2% in patients already symptomatic by virtue of having
body mass index (BMI) less than 20 kg/m2, or sex-specific
SKM index (SKMI) consistent with sarcopenia.15 In a valida-
tion study, weight loss and BMI generally discriminated
between patients with and without cachexia and associated
with survival.16 Thus, cachexia development and progression
can be monitored by tracking weight loss or weight loss with
BMI, or via more sophisticated quantitative and imaging mo-
dalities. Indeed, body composition measurements obtained
from computed tomography (CT) scans have emerged as a
powerful, prognostic methodology applicable across many
disease states, including PDAC.17–20 In many countries, CT
scans are routinely obtained in patients with unresectable
PDAC for staging and to monitor disease response to treat-
ment. Body composition measurements made from these im-
ages can equally be used to monitor treatment effects on
cachexia. CT measurements can detect low muscle mass, or
sarcopenia, as well as fatty muscle infiltration, or
myosteatosis. All of these, sarcopenia, sarcopenic obesity,
and myosteatosis are associated with decreased survival in
patients with malignancy.21–24
Despite a proliferation of body composition studies in the
literature, including in PDAC, fundamental questions regard-
ing cancer cachexia remain. These include whether all cancer
cachexia is similar across tumour types, what effects specific
treatments might have on cachexia course, and whether
muscle and fat are lost equally. Most studies aggregate
patients with a variety of tumour types or treatment modal-
ities, obviating any disease or treatment-specific effects.
Moreover, while there are considerable cross-sectional data
particularly on muscle, to date, there has been much less
work done to define the longitudinal development of
cachexia and much less focus on fat.
We posit that there are disease-specific, treatment-
specific, and tissue-specific mechanisms in cancer cachexia,
and thus we sought to characterize muscle and fat changes
in a controlled and highly homogenous population. We chose
patients with advanced PDAC on FOLFIRINOX chemotherapy.
The data indicate that there is diversity in cachexia pheno-
types even in this population, suggesting underlying diversity
in molecular and cellular drivers. Moreover, cachexia pheno-
types were unrelated to tumour response. Finally, our data
suggest that adipose tissue wasting, not just muscle wasting,
is an important influence on mortality from PDAC.
Materials and methods
This retrospective study was approved by the Indiana
University Institutional Review Board and was carried out in
compliance with the IU Standard Operating Procedures for
Research Involving Human Subjects. All data collection oc-
curred between 1 September 2015 and 29 November 2016.
Patient acquisition
All patients presenting to Indiana University Hospital
between the dates of 1 July 2010 and 31 August 2015 with
advanced PDAC treated with FOLFIRINOX as first-line therapy
with available survival data and adequate CT images for anal-
ysis were eligible for inclusion in the study. Advanced PDAC
was defined as PDAC that was not amenable to surgical
resection. Sixty-six patients were identified. Upon review, 13
patients were excluded: four with missing CT scans, six with
only a single CT scan, two with poor quality CT scans unable
to be analysed, and one treated with an alternative chemo-
therapy regimen prior to presentation at Indiana University.
This resulted in 53 total subjects in the study. Demographic,
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clinical, and survival data along with CT scans were collected
on these 53 subjects.
CT tissue mass analysis
Computed tomography images were analysed for cross-
sectional area (cm2) for SKM, intramuscular adipose tissue
(IMAT), visceral adipose tissue (VAT), and subcutaneous adi-
pose tissue (SCAT) mass at the level of the 3rd lumbar verte-
brae (L3)25 using Slice-O-Matic® software V4.3 (Tomovision,
Montreal, Quebec, Canada). Hounsfield unit (HU) thresholds
were set at 29 to +150 HU for SKM, 30 to 190 HU for
IMAT and SCAT, and 50 to 150 HU for VAT.26 Two consec-
utive images were analysed on all CT scans by a single inves-
tigator (J. K. K.). Approximately 25% of those images were
also analysed by a second investigator and inter-observer
variance was <1.8%. The mean of the two images was nor-
malized to height in metres2 to establish tissue-specific indi-
ces. Total adipose index (TAI) was calculated by adding
IMAT index, VAT index, and SCAT index. Sarcopenia was de-
fined as a SKMI <52.4 cm2/m2 for males and <38.5 cm2/m2
for females.21 Myosteatosis was defined as a mean SKM
radiodensity of <33 HU for patients with a BMI ≥25 kg/m2
and <41 HU for patients with a BMI <25 kg/m2.19 Estimates
of whole body stores for SKM, total adipose, and each adi-
pose compartment were obtained by applying the following
regression equations by Mourtzakis et al.27
Total body muscle mass kgð Þ ¼ 0:3 x ðskeletal muscle at L3 cm2 
þ6:06
Total body adipose mass kgð Þ ¼ 0:042 x adipose tissue at L3 cm2 
þ11:2
Obesity was defined by the World Health Organization
criteria.28 Patients were classified as having sarcopenic
obesity if they met the criteria for sarcopenia and obesity.
Total muscle measurements included the rectus abdominus,
external and internal oblique, transversus abdominus, psoas,
erector spinae, and quadratus lumborum.
Determination of disease response
Disease response to chemotherapy was determined by using
Response Evaluation Criteria in Solid Tumours criteria29 by a
single investigator (S. S.). Patients were classified into three
groups based on best response: regression of disease, stable
disease, and progression of disease.
Determination of cachexia phenotype
Serial CT scans were performed every 3 months per institu-
tion protocol. All CT scans from the time of diagnosis until
the end of the study were analysed and included in the data
analysis. A total of 298 CT scans were analysed. Tissue mass
measurements were graphed vs. time to identify any trends.
Trends in SKMI and TAI were noted and patients were divided
into three categories: No Wasting (NW), Fat-Only Wasting
(FW), and Muscle and Fat Wasting (MFW). Cut-offs for signif-
icant change was set at ≥5% increase or decrease from the
initial CT measurement to the final CT measurement. The
subjects were then re-categorized as needed based on this
cut-off threshold. Patients with a significant increase in one
category but significant decrease in another category were
defined as NW.
Statistical analysis
The primary outcome measure was overall survival, calculated
in months from the time of diagnosis to the time of death or
last follow-up. The main prognostic factor was cachexia phe-
notype, however, age, sex, disease extent, best chemotherapy
response, presence of sarcopenia, obesity, sarcopenic obesity,
and myosteatosis at diagnosis, and tumour location were also
examined. Age was dichotomized at the mean for Kaplan–
Meier and Cox proportional analysis. Results of Kaplan–Meier
survival analysis are reported as median survival with log base
P values. Results of Cox proportional analysis are reported as
hazard ratios with 95% confidence intervals.
Mean age, BMI, Eastern Cooperative Oncology Group
(ECOG) performance status,30 tissue indices, changes in tissue
indices, HU, total number of CT scans, and months between
initial and final CT scan were compared between cachexia phe-
notypes using analysis of variance. Tukey’s method was per-
formed when the analysis of variance revealed a difference
to identify where the difference occurred. Changes in BMI,
tissue indices, and HU were analysed by one-sample t-test to
evaluate for difference from zero. Sex, disease extent, disease
response, tumour location, obesity, sarcopenia, sarcopenic
obesity, and myosteatosis were compared between cachexia
phenotypes using Pearson’s chi-square test. All continuous
variables are reported as the mean with standard deviation,
with the exception of total number of CT scans and months
between initial and final CT scan, which are reported with
the range. All categorical variables are reported as the true
measurement with percentage.
Multivariate analysis was performed using generalized lin-
ear regression. All variables were included in the multivariate
analysis except sarcopenia and obesity. Age was dichotomized
at the mean for multivariate analysis. Results are reported as
difference in months of survival compared with the stated
reference with 95% confidence intervals and P values.
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All statistical analysis was performed using IBM SPSS
Statistics for Windows version 23.0 (SPSS, Chicago, IL).
Images for Kaplan–Meier curves and tissue trend graphs were
created using GraphPad Prism version 7 (GraphPad Software,
LaJolla, CA). Waterfall plots were created using Microsoft
Excel for Windows 2016 (Microsoft Corporation, Redman,
WA). Significance was set at a P value <0.05 for all results.
Results
Demographic and disease data
Demographic and disease data are summarized in Table 1.
Overall mean age was 59.5 (SD = 9.9) years. The majority
of the patients were male, 62.3%. Tumour, lymph node,
and metastasis staging convention in PDAC is such that lo-
cally advanced disease is stage III, T4NxM0, due to vascular
involvement. For patients with metastatic disease, primary
tumour and node status is frequently not assessed because
metastasis status informs stage, prognosis, and treatment;
that is, M1 is stage IV, irrespective of T and N stage. Here,
patients presented equally with locally advanced and meta-
static disease, 49% and 51%, respectively. At diagnosis, 33%
of patients showed ECOG performance status 0, and 67%
ECOG 1. The majority of patients had positive response to
chemotherapy with 43% having tumour regression and
40% having stable disease compared with 17% with tumour
progression. The pancreatic head (51%) was the most com-
mon place for the primary tumour followed by the body
(38%) then the tail (11%). Overall patients were less likely to
be obese (44%) or have sarcopenic obesity (11%) and equally
likely to have sarcopenia (49%) at presentation. A total of
296 CT scans were analysed for an overall mean of 5.6
(range = 2.0–18.0) scans per subject. Mean time between ini-
tial CT scan and final CT scan analysed was 11.1 months.
OMS was 14.7 months for the entire cohort (Figure 1A).
History of weight loss prior to presentation was not recorded
for the entire cohort and thus was uninformative.
Three cachexia phenotypes are identified
Based on SKMI and TAI trend analysis (Figure 2), three
distinct wasting patterns were identified: The majority of pa-
tients developed MFW, 64%, followed by NW, 19%, and FW,
17%. There was no difference between phenotypes for age,
sex, ECOG performance status, disease stage, disease re-
sponse, tumour location, obesity, sarcopenia, myosteatosis,
mean number of CT scans, or time between CT scans.
Sarcopenic obesity was more likely to be present in the FW
phenotype.
Table 1 Patient characteristics (N = 53)
Variable Overall
No Wasting
(19%)
Fat-Only Wasting
(17%)
Muscle and Fat
Wasting (64%) P value
Age, years (SD) 59.5 (9.9) 58.8 (7.7) 61.0 (12.4) 59.4 (10.0) 0.88
Sex
Male 33 7 5 13 0.81
Female 20 3 4 21
Disease extent
Locally advanced 26 3 6 17 0.28
Metastatic 27 7 3 17
Disease response
Regression 23 6 5 12 0.52
Stable 21 2 3 16
Progression 9 2 1 6
Tumour location
Head 27 2 6 19 0.22
Body 20 6 3 11
Tail 6 2 0 4
Obesity at diagnosis
Yes 18 2 4 12 0.51
No 35 8 5 22
Sarcopenia at diagnosis
Yes 26 5 7 14 0.15
No 27 5 2 20
Sarcopenic obesity at diagnosis
Yes 6 0 4 2 0.002
No 47 10 5 32
Myosteatosis
Yes 28 6 7 15 0.18
No 25 4 2 19
Mean number of CT scans (range) 5.6 6.9 (2–18) 4.2 (2–7) 5.6 (2–13) 0.21
Mean months between initial and final
CT scan (range)
11.1 13.1 (6.7–24.7) 11.2 (0.9–45.6) 10.5 (0.7–28.2) 0.71
CT, computed tomography.
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Morphometric analysis
Initial body composition measurements and changes are
summarized in Table 2. There was no difference in initial
BMI, IMAT index, VAT index, SCAT index, or TAI. A differ-
ence was observed in initial SKMI and SKM HU between
the groups (P = 0.036 and P = 0.045). Post hoc analysis re-
vealed the FW phenotype started with lower SKMI and
SKM HU measurements than the MFW phenotype (Table
S1). Figure 3 illustrates the tissue changes for each pa-
tient. The NW phenotype showed no significant losses in
any measured variable and actually showed significant
Figure 1 Univariate survival analysis reveals variables associated with decreased median overall survival (OS). Survival on x-axis plotted as time from
date of tissue-confirmed diagnosis for all plots. (A) Kaplan–Meier curve showing OS for entire patient cohort, which was 14.7 months (n = 53). (B) OS
differed by cachexia phenotype. No Wasting OS was 22.6 months (n = 10) vs. Fat-Only Wasting OS 13.0 months (n = 9) vs. Muscle and Fat Wasting
12.2 months (n = 34)(log rank P = 0.02). (C) OS for patients without sarcopenic obesity at time of initial computed tomography scan was 16.1 months
(n = 47) vs. those with sarcopenic obesity 10.4 months (n = 6)(log rank P = 0.04).
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increases in BMI, IMAT, SCAT, and TAI. The FW phenotype
showed significant losses in all adipose tissue compart-
ments and in total adipose tissue. The MFW phenotype
showed significant losses in all measured variables includ-
ing SKM HU.
Variables associated with overall survival
Univariate analysis showed that cachexia phenotype, chemo-
therapy response, and tumour location were associated with
survival. FW phenotype had an OMS of which was signifi-
cantly longer than FW and MFW (Figure 1B). FW and MFW
were associated with increased mortality when compared
with NW (Table 3). Presence of sarcopenic obesity on initial
CT scan was associated with a significantly decreased OMS
(Figure 1C). Other variables associated with decreased OMS
and increased risk of mortality were progression of disease
while on FOLFIRINOX therapy and primary tumours located
in the tail of the pancreas (Table 3).
Cachexia phenotype and chemotherapy response
are independent predictors of survival
Multivariate analysis showed cachexia phenotype, chemo-
therapy response, and tumour location to be independently
associated with overall survival. Development of FW is asso-
ciated with a mean decrease in survival of 9.9 months while
development of MFW is associated with a mean decrease in
survival of 8.8 months when compared with NW. Progression
of disease while on FOLFIRINOX was associated with a mean
decrease in survival of 7.0 months when compared with
regression of disease (Table 3).
Figure 2 Selective representative computed tomography (CT) images with tag overlay and corresponding tissue mass vs. time graphs from individual
patients in each cachexia phenotype at the L3 level. (A) No changes in any tissue mass can be visual appreciated on serial CT scans for the No Wasting
phenotype. Graphing tissue masses vs. time shows that there is an initial increase in total adipose and visceral adipose mass with return to starting
values at the end of the study. (B) Decreases in subcutaneous adipose and visceral adipose can be visually appreciated on serial CT scans in the
Fat-Only Wasting phenotype. Graphic representation of this patient shows trends towards decreased subcutaneous, visceral, and total adipose mass
by the end of the study. Statistical analysis would confirm these changes to be significant (≥5%). (C) Significant decrease in skeletal muscle, subcuta-
neous, and visceral adipose tissue can be visually appreciated on serial CT scans in the Muscle and Fat Wasting phenotype. Graphic representation of
tissue mass vs. time shows trends towards decreases in all tissues. Statistically analysis would confirm this patient to have significant losses in skeletal
muscle, subcutaneous, visceral, and total adipose masses (≥5%).
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Rate of cachexia is not associated with survival
Median time to onset of cachexia was 71.5 days. Comparing
survival of patients who had early onset cachexia, before
the median, and those that had late onset cachexia, after
the median, showed no difference, 16.1 vs. 12.2 months
(P = 0.88), or risk of mortality (HR = 1.06; 95% confidence
interval = 0.50–2.24).
Discussion
This study is the first to examine the longitudinal changes in
body composition and the associations of these changes with
survival in a highly homogeneous population—patients with
advanced PDAC undergoing FOLFIRINOX chemotherapy as
first-line treatment. Using the traditional definition of >5%
body weight loss to define cachexia, only 56.6% of patients
in this cohort developed cachexia over the course of their
treatment. However, using a definition of ≥5% loss of muscle
and/or fat mass, the prevalence of cachexia was 81%. This is
consistent with previously published data and provides
further evidence that cachexia treatment is a major unmet
need of patients with advanced PDAC 14. The study also iden-
tified three different cachexia phenotypes, NW, FW, and
MFW. The study identifies a subset of patients, NW, who
appear resistant to cachexia and as a result have significantly
improved survival. In addition, the study showed fat loss to
be an equally important factor on survival as muscle loss.
To the best of the authors’ knowledge, this is the first
paper to demonstrate different wasting phenotypes within
a homogenous disease/treatment population. The identifica-
tion of these phenotypes is important because their existence
suggests molecular and/or genetic heterogeneity among the
hosts or the tumours as the driving force for each wasting
pattern. Although we cannot posit specific mechanisms from
this limited analysis, we speculate that differences in molecu-
lar drivers could be responsible. For example, various cyto-
kines have been implicated in cancer cachexia, including
Table 2 Baseline body composition and changes
Variable (SD)
Overall
(SD)
No
Wasting
P
valuea
Fat-Only
Wasting P valuea
Muscle and
Fat Wasting
P
valuea
P value among
cachexia
phenotypes
Initial BMI
(kg/m2)
28.8 (7.3) 26.3 (4.8) 28.7 (12.4) 29.5 (6.1) 0.48
BMI change
(kg/m2)
2.9 (5.9) 2.2 (2.7) 0.028 5.5 (11.2) 0.129 3.7 (3.5) <0.001 0.005
BMI % change 8.3 (15.0) 8.3 (9.4) 0.021 12.5 (19.5) 0.058 12.1 (11.7) <0.001 <0.001
Initial SKMI
(cm2/m2)
46.9 (9.5) 44.4 (8.3) 40.8 (7.1) 49.2 (9.6) 0.036
SKM change (kg) 3.5 (5.9) 3.7 (5.4) 0.056 0.7 (1.4) 0.144 6.8 (3.9) <0.001 <0.001
SKMI % change 7.2 (13.3) 10.1 (14.6) 0.056 2.2 (3.5) 0.911 14.8 (6.5) <0.001 <0.001
Initial IMATI
(cm2/m2)
4.1 (2.6) 4.5 (2.9) 4.1 (2.9) 3.9 (2.6) 0.85
IMAT change
(kg)
0.09 (0.3) 0.1 (0.1) 0.003 0.2 (0.2) 0.034 0.1 (0.3) 0.006 0.005
IMATI % change 13.0 (78.2) 44.6 (52.6) 0.025 40.0 (25.5) 0.001 22.7 (86.1) 0.133 0.027
Initial VATI
(cm2/m2)
49.6 (34.6) 48.5 (41.8) 31.9 (18.0) 54.6 (34.9) 0.22
VAT change (kg) 2.1 (2.8) 0.8 (2.0) 0.240 2.0 (1.9) 0.016 2.9 (2.7) <0.001 <0.001
VATI % change 28.5 (64.9) 50.3 (103.0) 0.157 49.6 (33.9) 0.001 46.1 (33.8) <0.001 <0.001
Initial SCATI
(cm2/m2)
71.3 (46.2) 57.5 (28.4) 53.0 (30.4) 80.2 (51.8) 0.169
SCAT change
(kg)
2.8 (3.9) 1.3 (1.0) 0.003 2.0 (2.2) 0.026 4.3 (4.0) <0.001 <0.001
SCATI % change 27.8 (47.9) 36.0 (62.8) 0.103 34.3 (27.4) 0.002 44.8 (28.6) <0.001 <0.001
Initial TAI
(cm2/m2)
120.9 (61.7) 106.0 84.9 (41.3) 134.8 (63.4) 0.066
TA change (kg) 5.0 (5.9) (59.1) 0.028 4.1 (4.0) 0.015 7.3 (5.2) <0.001 <0.001
TAI % change 29.5 (49.8) 2.2 (2.6) 0.118 46.2 (27.1) <0.001 46.2 (27.1) <0.001 <0.001
37.8 (69.1)
Initial SKM HU 35.0 (7.1) 34.3 (6.5) 30.0 (7.3) 36.5 (6.8) 0.045
SKM HU change 0.7 (8.3) 1.6 (5.0) 0.34 9.6 (12.5) 0.089 3.2 (5.3) 0.001 <0.001
SKM HU
% change
0.04 (29.3) 6.3 (16.2) 0.247 38.1 (48.7) 0.078 8.3 (15.1) 0.003 <0.001
Abbreviations: BMI, body mass index; SKMI, skeletal muscle index; IMATI, intramuscular adipose tissue index; VATI, visceral adipose tissue
index; SCATI, subcutaneous adipose tissue index; TA, total adipose; TAI, total adipose index; SKM HU, skeletal muscle Hounsfield units.
Bolded values are statistically significant (P < 0.05).
aThis is the P value for in group comparison and represents whether the changes are significant within the group.
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tumour necrosis factor-alpha, interleukin-1, interleukin-6
(IL-6), interferon-gamma, ciliary neurotrophic factor, and
activin.31–37 Tumours express varying levels of such cytokines,
one potential source of variation. Furthermore, germline
nucleotide polymorphisms in genes linked to cytokine
production rates are associated with the development of
cachexia,38 specifically in regard to IL-6 in the setting of
pancreatic cancer,39 suggesting that patient genetics might
be at the root of cachexia phenotype. Future studies focusing
on molecular and genetic differences between PDAC tumours
or patients and associated with specific cachexia phenotypes
are indicated, as therapies targeting the precise cause of
cachexia are essential to achieve optimal outcomes.
The second major finding of this study is the lack of differ-
ence in survival between patients who lost muscle and fat
and patients who lost only fat. The prominent theory in
cachexia is that muscle loss is the major complication in
cancer cachexia and to date cachexia research has mainly
focused on muscle. The data presented here suggest that
fat has an equivalent role, as developing the FW phenotype
conferred a decreased survival that was not significantly
different than the MFW phenotype.
Adipose tissue has long been seen as an energy regulating
tissue with additional responsibilities of mechanical protec-
tion and temperature regulation. This changed with the
discovery of leptin production by adipose tissue, and it was
recognized that fat had important endocrine functions as
well.40 Since this discovery, adipose tissue has been shown
to express and secrete a number of different signalling mole-
cules including the cachexia-associated cytokines TNF-α and
IL-6. The loss of adipose tissue in cancer cachexia has also
been shown to be accompanied by changes in gene expres-
sion pathways regulating energy turnover.41 Although it has
been shown that high fat loss rate is associated with
decreased survival in patients with PDAC undergoing a vari-
ety of treatment regimens,42 the data presented here show
that fat loss is equivalent to muscle loss for mortality risk.
Previous studies show that sarcopenia, sarcopenic obesity,
and myosteatosis at diagnosis are associated with decreased
survival in pancreatic cancer.22–24 Of these variables, in our
study, only sarcopenic obesity associated with mortality
although it was not significant in the multivariate analysis
(Table 3). While not statistically significant, all of these vari-
ables did trend in the direction of having an impact on
Figure 3 Cachexia phenotypes show distinct patterns of tissue wasting. (A) Breakdown of skeletal muscle index (SKMI) and total adipose index (TAI)
changes. Mean SKMI and TAI changes for the No Wasting (NW) phenotype were +4.3 cm2/m2 (P = 0.056) and +16.8 cm2/m2 (P = 0.03) vs. mean SKMI
and TAI change for the Fat-Only Wasting (FW) phenotype were +0.8 cm2/m2 (P = 0.788) and 37.7 cm2/m2 (P = 0.014) and Muscle and Fat Wasting
(MFW) phenotype mean SKMI and TAI changes of 7.5 cm2/m2 (P < 0.001) and 58.6 cm2/m2 (P < 0.001). (B) Percent changes in SKMI and TAI for
each cachexia phenotype. NW had increases in SKMI and TAI percent change of +10.1% (P = 0.056) and +37.8% (P = 0.118) while FW showed SKMI
percent change of +2.2% (P = 0.911) and a decrease in TAI of 46.2% (P < 0.001) and MFW’s SKMI and TAI percent change were 14.8%
(P < 0.001) and 46.2% (P < 0.001). Skeletal muscle is represented in red, intramuscular adipose tissue in green, visceral adipose tissue in yellow,
and subcutaneous adipose tissue in blue.
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survival. In a large patient cohort, these variables would likely
show statistical significance and be in line with previously
published data. Our data show that development of FW or
MFW over the treatment course was associated with de-
creased survival, independent of tumour response to treat-
ment. Thus, cachexia response and phenotype could be
independent of tumour response to therapy, suggesting
mechanisms of cachexia that are separable from tumour
growth.
Finally, this study also gives perspective onto how we
should diagnose cachexia. The traditional definition of ca-
chexia is unintentional weight loss of >5% over 6 months.
Such information is not always captured at presentation
and relies upon accurate patient recall, which is always sub-
ject to bias. Here, using CT scans and data collected after
treatment onset, 56.6% of patients experienced >5% body
weight loss over treatment course, while 81% of patients ex-
hibited ≥5% loss of muscle or fat mass. No patient in the
NW phenotype had >5% body weight loss. Applying the
>5% body weight loss criterion to the FW and MFW
phenotypes would have classified 5/9 and 25/34 patients
as developing cachexia. This would have missed 13/43 or
30% of patients with significant muscle or fat wasting. One
explanation could be that patients with advanced PDAC
can develop significant tumour burden and metastases,
growth of liver and spleen, and production of ascites, all of
which would obscure fat and muscle tissue wasting if only
weight change is monitored. Thus, use of CT body morpho-
metric measurements is a more accurate way of determin-
ing a patient’s cachexia status.
Of course, our study has limitations. It is a retrospective
study and therefore is subject to all limitations associated
with retrospective studies. While the CT scans were reliable
and available for objective analysis, certain potentially
important clinical data were incompletely recorded (e.g. his-
tory of weight loss at presentation) or not collected (e.g. cy-
tokine levels and CRP). This analysis was also performed on
an intent-to-treat basis. The precise dose modifications/re
ductions and reasons for altering dose (e.g. adverse events
vs. patient choice), while aggressively sought, were
Table 3 Survival analysis (overall median survival = 14.7 months)
Survival Univariate analysis Multivariate analysis
Variable Median OS (months) P value
Hazard
ratio 95% CI P value
Months
difference 95% CI P value
Age
<59.5 years 16.1 0.066 Reference Reference Reference
≥59.5 years 12.8 1.76 0.96–3.23 0.07 1.41 5.5–2.7 0.50
Gender
Female 18.9 0.56 Reference Reference Reference
Male 13.0 1.2 0.65–2.21 0.56 0.94 5.2–3.4 0.67
Disease extent
Locally 17.0 0.23 Reference Reference Reference
Advanced metastatic 13.0 1.43 0.80–2.64 0.23 0.30 4.7–5.3 0.91
Chemotherapy response
Regression 18.0 0.001 Reference Reference Reference 3.3 0.53
Stable 16.1 1.3 0.7–2.5 0.46 1.56 –2.5 0.02
Progression 8.3 2.1 1.4–3.3 0.001 6.98 12.8 to 1.1
Sarcopenia
No 17.0 0.32 Reference Reference N/I
Yes 13.0 1.35 0.74–2.46 0.32
Obesity
No 14.2 0.90 Reference Reference N/I
Yes 17.0 0.96 0.50–1.85 0.90
Sarcopenic obesity
No 16.1 0.04 Reference Reference 0.05 Reference 8.7–7.3 0.87
Yes 10.4 2.47 1.0–6.1 0.69
Myosteatosis
No 17.8 0.21 Reference Reference 0.21 Reference
Yes 14.2 1.48 0.8–2.74 3.9 8.3–0.54 0.09
Tumour location
Head 17.8 0.02 Reference Reference 0.58 Reference 7.5 0.28
Body 14.7 1.2 0.6–2.3 0.01 2.7 –2.2 0.06
Tail 10.4 2.1 1.2–3.8 7.1 14.5–0.34
Cachexia phenotype
No Wasting 22.6 0.02 Reference Reference 0.008 Reference 18.5 to 2.2 0.01
Fat-Only Wasting
Muscle and Fat Wasting
13.0
12.2
5.2
1.8
1.5–17.3
1.1–2.9
0.02 10.4
9.9
15.6 to 4.3 0.001
Abbreviations: OS, overall survival; CI, confidence interval; F test for model significance = 0.009.
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insufficiently detailed in the charts to include in this analysis.
Additionally, complete accountings of co-morbidities and
concomitant medications were not available, and the au-
thors recognize that some patients may have had significant
co-morbidities that contributed to the outcome. However,
ECOG performance status was no different across cachexia
phenotypes, and all patients were ECOG 0 or 1 at treatment
onset consistent with prescribing practices for FOLFIRINOX.
Thus, it seems unlikely that those patients exhibiting either
cachexia phenotype had significantly more other disease
burden than patients with NW. Additionally, this study is
susceptible to length time bias. This is an unavoidable bias
because there is no accurate screening test for PDAC and
there is no way to know exactly when the disease process
began. All patients in the current study presented with ad-
vanced PDAC. Given the high rate of cachexia in PDAC, it
can be assumed that the initial CT scan was obtained after
some degree of cachexia developed. However, the authors
do not believe this would have an effect on the overall
results. Finally, this study evaluated 53 patients and this
sample size may have limited the study’s power to detect
the effects of some variables. While this sample size is large
enough to safely say that the differences found are truly
present, the authors recognize that it is not large enough
to eliminate type II error and that some real differences
were likely not detected.
Our data identify three distinct systemic responses to
PDAC treated with FOLFIRINOX. All patients with the NW
phenotype show all the patients had significant increase
in muscle, fat, or both tissues during the course of treat-
ment, thus establishing a cachexia-resistant phenotype.
Patients with the FW phenotype presented with lower
SKMI, which was possibly due to muscle wasting prior to
the initial scan. This group, however, did not lose any ad-
ditional muscle throughout the course of the disease,
while patients with the MFW phenotype lost muscle and
fat congruently. Moreover, analysis of days from diagnosis
to measurable tissue lost showed no difference between
FW and MFW (P = 0.67). Therefore, we conclude that
these are two distinct phenotypes of cachexia, each con-
tributing to PDAC mortality.
We studied only patients with PDAC who received
FOLFIRINOX as first-line treatment, and perhaps this treat-
ment influenced cachexia presentation. Preclinical data
indicate that certain chemotherapy regimens, including
FOLFIRI, can induce cachexia in the absence of can-
cer.43,44 Currently, there are no published experimental
data linking FOLFIRINOX to the development of cachexia,
and cachexia develops in the vast majority of patients
with PDAC regardless of treatment.10 Thus, it is unlikely
that FOLFIRINOX was solely responsible for the cachexia
observed. As well, patients with the NW phenotype also
received FOLFIRINOX, strengthening the conclusion that
the cachexia was disease-driven and not treatment-
driven. Nevertheless, similar studies involving patients un-
dergoing other chemotherapy regimens and in other ma-
lignancies must be done before these results can be
generalized.
To the best of our knowledge, this study uniquely
shows distinct cachexia phenotypes in PDAC, a single can-
cer diagnosis, treated with FOLFIRINOX, a reasonably ho-
mogeneous regimen. The measurements described here
will be used locally to guide clinical trial design for anti-
cachexia trials in the setting of FOLFIRINOX. Our prelimi-
nary power analyses suggest that adipose wasting will be
more sensitive an indicator than muscle loss, requiring
fewer patients. As well, the fact that multiple phenotypes
emerged in this uniform population raises suspicion that
molecular and/or genetic heterogeneity is present in the
tumours or in the hosts, and furthermore, that discovery
of these differences could lead to more targeted thera-
pies. As such, identifying differences and developing indi-
vidualized therapy could be critical to optimize care of
patients with cachexia. Finally, our study also emphasizes
the important role of adipose wasting in PDAC mortality.
Research focusing on fat and fat loss in cachexia will be
vital to understanding the disease process. Future studies
should focus on parsing molecular subtypes of PDAC ca-
chexia and tumour, host, and treatment factors modulat-
ing the systemic response.
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